Marc Rothenberg, MD, PhD, has received the American Academy of Allergy, Asthma & Immunology (AAAAI) 2023 Distinguished Scientist Award. Rothenberg will be recognized during the 2023 AAAAI Annual Meeting on February 24-26.
Rothenberg is the director of the Division of Allergy and Immunology and the Cincinnati Center of Eosinophilic Disorders (CCED) at Cincinnati Children’s Hospital Medical Center and principal investigator and co-leader of the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).
The prestigious AAAAI Distinguished Scientist Award recognizes outstanding scientific contributions to the field of allergy/immunology that have significantly advanced allergy/immunology research and outcomes for patients, as well as leadership contributions to the field. Rothenberg is being recognized for his significant contributions to advances of a new drug treatment for anti-eosinophil therapeutics and novel therapies for patients suffering from severe immune-mediated diseases.
“Marc has been a powerful mover in the field of allergy and immunology, especially eosinophilic gastrointestinal disorders, making him especially deserving of this honor. CEGIR is lucky to have Marc at its helm," says Glenn Furuta, MD, co-leader of CEGIR.
The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Office of Rare Diseases Research (ORDR). CEGIR is funded under grant number U54AI117804 as a collaboration between NCATS, the National Institute of Allergy and Infectious Diseases (NIAID), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
